Pharmacotherapy of alcoholism – an update on approved and off-label medications

References

• World Health Organization. International classification of diseases, 10th revision (ICD-10). 2010 [cited 2013 Dec 16]. Available from: http://apps.who.int/classifications/icd10/browse/2010/en
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Publishing; 2000. Text Revision
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013.
   Google Scholar
• Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015 Aug 1;72(8):757–766.
   PubMed Web of Science ®Google Scholar
• Gowing LR, Ali RL, Allsop S, et al. Global statistics on addictive behaviours: 2014 status report. Addiction. 2015 Jun;110(6):904–919.
   PubMed Web of Science ®Google Scholar
• Grant BF, Stinson FS, Dawson DA, et al. Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004 Apr;61(4):361–368.
   PubMed Web of Science ®Google Scholar
• Hasin DS, Stinson FS, Ogburn E, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007 Jul;64(7):830–842.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005 Jun;62(6):617–627.
   PubMed Web of Science ®Google Scholar
• Pirkola SP, Poikolainen K, Lonnqvist JK. Currently active and remitted alcohol dependence in a nationwide adult general population–results from the finnish health 2000 study. Alcohol Alcohol. 2006 May–Jun;41(3):315–320.
   PubMed Web of Science ®Google Scholar
• Soyka M, Kranzler HR, Hesselbrock V, et al. Guidelines for biological treatment of substance use and related disorders, part 1: alcoholism, first revision. World J Biol Psychiatry. 2016 Dec;23:1–34.
   Google Scholar
• Donoghue K, Elzerbi C, Saunders R, et al. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 2015 Jun;110(6):920–930.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014 May 14;311(18):1889–1900.
   PubMed Web of Science ®Google Scholar
• Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013 Feb;108(2):275–293.
   PubMed Web of Science ®Google Scholar
• Rosner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;9:CD004332.
   PubMed Web of Science ®Google Scholar
• Rosner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;12:CD001867.
   PubMed Web of Science ®Google Scholar
• Heilig M, Epstein DH, Nader MA, et al. Time to connect: bringing social context into addiction neuroscience. Nat Rev Neurosci. 2016 Sep;17(9):592–599.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology (Berl). 2000 May;149(4):327–344.
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M. Neurobiology of addiction. London: Academic Press; 2006.
   Google Scholar
• Noronha ABC, Cui C, Harris RA, et al., editors. Neurobiology of alcohol dependence. London: Academic Press ; 2014.
   Google Scholar
• Nutt D, Nestor L. Addiction. Kettering: Oxford University Press; 2013.
   Google Scholar
• Petrakis IL. A rational approach to the pharmacotherapy of alcohol dependence. J Clin Psychopharmacol. 2006 Dec;26(Suppl 1):S3–12.
   PubMed Web of Science ®Google Scholar
• Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. 2009 Apr;89(2):649–705.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Vengeliene V. New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci. 2013;13:583–609.
   PubMedGoogle Scholar
• Hillemacher T, Leggio L, Heberlein A. Investigational therapies for the pharmacological treatment of alcoholism. Expert Opin Investig Drugs. 2015 Jan;24(1):17–30.
   PubMed Web of Science ®Google Scholar
• Kwako LE, Spagnolo PA, Schwandt ML, et al. The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology. 2015 Mar 13;40(5):1053–1063.
   PubMed Web of Science ®Google Scholar
• Augier E, Dulman RS, Damadzic R, et al. The GABAB positive allosteric modulator ADX71441 attenuates alcohol self-administration and relapse to alcohol seeking in rats. Neuropsychopharmacology. 2017 Apr 12.
   PubMed Web of Science ®Google Scholar
• Koob GF. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res. 2003 Feb;27(2):232–243.
   PubMed Web of Science ®Google Scholar
• Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci. 2002 May 1;22(9):3332–3337.
   PubMed Web of Science ®Google Scholar
• Bassareo V, Musio P, Di Chiara G. Reciprocal responsiveness of nucleus accumbens shell and core dopamine to food- and drug-conditioned stimuli. Psychopharmacology (Berl). 2011 Apr;214(3):687–697.
   PubMed Web of Science ®Google Scholar
• Di Chiara G, Bassareo V. Reward system and addiction: what dopamine does and doesn’t do. Curr Opin Pharmacol. 2007 Feb;7(1):69–76.
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Martin-Fardon R, Weiss F. Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology. 2002 Sep;27(3):391–399.
   PubMed Web of Science ®Google Scholar
• Jarjour S, Bai L, Gianoulakis C. Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area. Alcohol Clin Exp Res. 2009 Jun;33(6):1033–1043.
   PubMed Web of Science ®Google Scholar
• Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem. 2004;4(1):39–50.
   PubMed Web of Science ®Google Scholar
• Marcinkiewcz CA, Lowery-Gionta EG, Kash TL. Serotonin’s complex role in alcoholism: implications for treatment and future research. Alcohol Clin Exp Res. 2016 Jun;40(6):1192–1201.
   PubMed Web of Science ®Google Scholar
• Goodwani S, Saternos H, Alasmari F, et al. Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder. Neurosci Biobehav Rev. 2017 Jun;77:14–31.
   PubMed Web of Science ®Google Scholar
• Hopf FW. Do specific NMDA receptor subunits act as gateways for addictive behaviors? Genes Brain Behav. 2017 Jan;16(1):118–138.
   PubMed Web of Science ®Google Scholar
• Costa ET, Soto EE, Cardoso RA, et al. Acute effects of ethanol on kainate receptors in cultured hippocampal neurons. Alcohol Clin Exp Res. 2000 Feb;24(2):220–225.
   PubMed Web of Science ®Google Scholar
• Crowder TL, Ariwodola OJ, Weiner JL. Ethanol antagonizes kainate receptor-mediated inhibition of evoked GABA(A) inhibitory postsynaptic currents in the rat hippocampal CA1 region. J Pharmacol Exp Ther. 2002 Dec;303(3):937–944.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Tabakoff B. Ethanol abuse, dependence, and withdrawal: neurobiology and clinical implications. In: Davis K, Charney D, Coyle JT, et al., editors. Psychopharmacology: a fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 1425–1443.
   Google Scholar
• Moghaddam B, Bolinao ML. Biphasic effect of ethanol on extracellular accumulation of glutamate in the hippocampus and the nucleus accumbens. Neurosci Lett. 1994 Aug 29;178(1):99–102.
   PubMed Web of Science ®Google Scholar
• EMA. Guideline on the development of medicinal products for the treatment of alcohol dependence. London: European Medicines Agency; 2010.
   Google Scholar
• Ferri M, Amato L, Davoli M. Alcoholics anonymous and other 12-step programmes for alcohol dependence. Cochrane Database Syst Rev. 2006;3:CD005032.
   PubMed Web of Science ®Google Scholar
• Kaner EF, Beyer F, Dickinson HO, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2007;2:CD004148.
   PubMed Web of Science ®Google Scholar
• Klimas J, Tobin H, Field CA, et al. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Cochrane Database Syst Rev. 2014;12:CD009269.
   PubMed Web of Science ®Google Scholar
• Lui S, Terplan M, Smith EJ. Psychosocial interventions for women enrolled in alcohol treatment during pregnancy. Cochrane Database Syst Rev. 2008;3:CD006753.
   Google Scholar
• McQueen J, Howe TE, Allan L, et al. Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev. 2009;3:CD005191.
   Google Scholar
• Huber CA, Maierhofer K, Wiesbeck GA. Chancen für psychosoziale und psychotherapeutische Interventionsmöglichkeiten durch eine multiprofessionelle Versorgungsumgebung. Suchtmed. 2015;17:179–184.
   Google Scholar
• Smedslund G, Berg RC, Hammerstrom KT, et al. Motivational interviewing for substance abuse. Cochrane Database Syst Rev. 2011;5:CD008063.
   PubMed Web of Science ®Google Scholar
• Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs. 2009 Jul;70(4):516–527.
   PubMed Web of Science ®Google Scholar
• Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 3;295(17):2003–2017.
   PubMed Web of Science ®Google Scholar
• Mann K, Lemenager T, Hoffmann S, et al. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013 Nov;18(6):937–946.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Wilford BB, Falk DE, et al. Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety. Substance Abuse. 2016 Apr–Jun;37(2):286–298.
   PubMed Web of Science ®Google Scholar
• Sinclair JM, Chambers SE, Shiles CJ, et al. Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. Drug Safety. 2016 Jul;39(7):627–645.
   PubMed Web of Science ®Google Scholar
• Mutschler J, Abbruzzese E, Witt SH, et al. Functional polymorphism of the dopamine beta-hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients. J Clin Psychopharmacol. 2012 Aug;32(4):578–580.
   PubMed Web of Science ®Google Scholar
• Suh JJ, Pettinati HM, Kampman KM, et al. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006 Jun;26(3):290–302.
   PubMed Web of Science ®Google Scholar
• Skinner MD, Lahmek P, Pham H, et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366.
   PubMed Web of Science ®Google Scholar
• Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A veterans administration cooperative study. JAMA. 1986 Sep 19;256(11):1449–1455.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999 Apr 14;281(14):1318–1325.
   PubMed Web of Science ®Google Scholar
• Hughes JC, Cook CC. The efficacy of disulfiram: a review of outcome studies. Addiction. 1997 Apr;92(4):381–395.
   PubMed Web of Science ®Google Scholar
• Krampe H, Stawicki S, Wagner T, et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res. 2006 Jan;30(1):86–95.
   PubMed Web of Science ®Google Scholar
• Sellers EM, Naranjo CA, Harrison M, et al. Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther. 1983 Dec;34(6):822–826.
   PubMed Web of Science ®Google Scholar
• Brewer C, Streel E, Skinner M. Supervised disulfiram’s superior effectiveness in alcoholism treatment: ethical, methodological, and psychological aspects. Alcohol Alcohol. 2017 Mar;52(2):213–219.
   PubMed Web of Science ®Google Scholar
• Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction. 1995 Sep;90(9):1179–1188.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997 Feb;18(2):54–59.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Pendyala G, Abarca C, et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med. 2005 Jan;11(1):35–42.
   PubMed Web of Science ®Google Scholar
• Frye MA, Hinton DJ, Karpyak VM, et al. Anterior cingulate glutamate is reduced by acamprosate treatment in patients with alcohol dependence. J Clin Psychopharmacol. 2016 Dec;36(6):669–674.
   PubMed Web of Science ®Google Scholar
• Harris BR, Gibson DA, Prendergast MA, et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcohol Clin Exp Res. 2003 Nov;27(11):1724–1735.
   PubMed Web of Science ®Google Scholar
• Cano-Cebrian MJ, Zornoza-Sabina T, Guerri C, et al. Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus. Naunyn Schmiedebergs Arch Pharmacol. 2003 Oct;368(4):324–327.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Vengeliene V, Jandeleit B, et al. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology. 2014 Mar;39(4):783–791.
   PubMed Web of Science ®Google Scholar
• Schuster R, Koopmann A, Grosshans M, et al. Association of plasma calcium concentrations with alcohol craving: new data on potential pathways. Eur Neuropsychopharmacol. 2017 Jan;27(1):42–47.
   PubMed Web of Science ®Google Scholar
• Mann K, Hoffmann S, Pawlak CR. Does acamprosate really produce its anti-relapse effects via calcium? No support from the PREDICT study in human alcoholics. Neuropsychopharmacology. 2016 Feb;41(3):659–660.
   PubMed Web of Science ®Google Scholar
• Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996 Aug;53(8):673–680.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006 Aug;40(5):383–393.
   PubMed Web of Science ®Google Scholar
• COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study. Alcohol Clin Exp Res. 2003 Jul;27(7):1123–1131.
   PubMed Web of Science ®Google Scholar
• Roos CR, Witkiewitz K. Adding tools to the toolbox: the role of coping repertoire in alcohol treatment. J Consult Clin Psychol. 2016 Jul;84(7):599–611.
   PubMed Web of Science ®Google Scholar
• Glockner-Rist A, Lemenager T, Mann K. Reward and relief craving tendencies in patients with alcohol use disorders: results from the PREDICT study. Addict Behav. 2013 Feb;38(2):1532–1540.
   PubMed Web of Science ®Google Scholar
• Nutt DJ. The role of the opioid system in alcohol dependence. J Psychopharmacol. 2014 Jan;28(1):8–22.
   PubMed Web of Science ®Google Scholar
• Dai X, Thavundayil J, Gianoulakis C. Differences in the peripheral levels of beta-endorphin in response to alcohol and stress as a function of alcohol dependence and family history of alcoholism. Alcohol Clin Exp Res. 2005 Nov;29(11):1965–1975.
   PubMed Web of Science ®Google Scholar
• Marinelli PW, Bai L, Quirion R, et al. A microdialysis profile of Met-enkephalin release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res. 2005 Oct;29(10):1821–1828.
   PubMed Web of Science ®Google Scholar
• Marinelli PW, Lam M, Bai L, et al. A microdialysis profile of dynorphin A(1-8) release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res. 2006 Jun;30(6):982–990.
   PubMed Web of Science ®Google Scholar
• Marinelli PW, Quirion R, Gianoulakis C. An in vivo profile of beta-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol. Neuroscience. 2004;127(3):777–784.
   PubMed Web of Science ®Google Scholar
• Oswald LM, Wand GS. Opioids and alcoholism. Physiol Behav. 2004 Apr;81(2):339–358.
   PubMed Web of Science ®Google Scholar
• Adcock RA, Thangavel A, Whitfield-Gabrieli S, et al. Reward-motivated learning: mesolimbic activation precedes memory formation. Neuron. 2006 May 4;50(3):507–517.
   PubMed Web of Science ®Google Scholar
• Bencherif B, Wand GS, McCaul ME, et al. Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry. 2004 Feb 1;55(3):255–262.
   PubMed Web of Science ®Google Scholar
• Heinz A, Reimold M, Wrase J, et al. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry. 2005 Jan;62(1):57–64.
   PubMed Web of Science ®Google Scholar
• Hubbell CL, Czirr SA, Hunter GA, et al. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol. 1986 Jan–Feb;3(1):39–54.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Jaffe AJ, Rode S, et al. Experience of a “slip” among alcoholics treated with naltrexone or placebo. Am J Psychiatry. 1996 Feb;153(2):281–283.
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992 Nov;49(11):876–880.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004 Jul;28(7):1051–1059.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005 Apr 6;293(13):1617–1625.
   PubMed Web of Science ®Google Scholar
• Anton RF. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics. 2008 Jun;9(6):655–658.
   PubMed Web of Science ®Google Scholar
• Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003 Aug;28(8):1546–1552.
   PubMed Web of Science ®Google Scholar
• Oslin DW, Leong SH, Lynch KG, et al. Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial. JAMA Psychiatry. 2015 May;72(5):430–437.
   PubMed Web of Science ®Google Scholar
• Hermann D, Hirth N, Reimold M, et al. Low mu-opioid receptor status in alcohol dependence identified by combined positron emission tomography and post-mortem brain analysis. Neuropsychopharmacology. 2017 Feb;42(3):606–614.
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003 Jan;60(1):92–99.
   PubMed Web of Science ®Google Scholar
• Fitzgerald N, Angus K, Elders A, et al. Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addiction. 2016 Aug;111(8):1477–1487.
   PubMed Web of Science ®Google Scholar
• Mann K, Torup L, Sorensen P, et al. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol. 2016 Dec;26(12):1941–1949.
   PubMed Web of Science ®Google Scholar
• Naudet F, Palpacuer C, Boussageon R, et al. Evaluation in alcohol use disorders - insights from the nalmefene experience. BMC Med. 2016 Aug 18;14(1):119.
   PubMed Web of Science ®Google Scholar
• Soyka M, Friede M, Schnitker J. Comparing nalmefene and naltrexone in alcohol dependence: are there any differences? Results from an indirect meta-analysis. Pharmacopsychiatry. 2016 Nov;49(6):261–262.
   PubMed Web of Science ®Google Scholar
• Soyka M. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother. 2016 Mar;17(4):619–626.
   PubMed Web of Science ®Google Scholar
• Walker BM, Koob GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology. 2008 Feb;33(3):643–652.
   PubMed Web of Science ®Google Scholar
• Walker BM, Valdez GR, McLaughlin JP, et al. Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol. 2012 Jun;46(4):359–370.
   PubMed Web of Science ®Google Scholar
• Walker BM, Zorrilla EP, Koob GF. Systemic κ-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addict Biol. 2011 Jan;16(1):116–119.
   PubMed Web of Science ®Google Scholar
• EMA. Selincro (nalmefene): summary of product characteristics. London: European Medicines Agency; 2014.
   Google Scholar
• Charlet K, Heinz A. Harm reduction-a systematic review on effects of alcohol reduction on physical and mental symptoms. Addict Biol. 2016 Jun 29.
   PubMedGoogle Scholar
• Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999 Aug;56(8):719–724.
   PubMed Web of Science ®Google Scholar
• Anton RF, Pettinati H, Zweben A, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004 Aug;24(4):421–428.
   PubMed Web of Science ®Google Scholar
• Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res. 2007 Jul;31(7):1179–1187.
   PubMed Web of Science ®Google Scholar
• Gual A, He Y, Torup L, et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013 Nov;23(11):1432–1442.
   PubMed Web of Science ®Google Scholar
• Mann K, Bladstrom A, Torup L, et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013 Apr 15; 73(8):706–713.
   PubMed Web of Science ®Google Scholar
• van den Brink W, Sorensen P, Torup L, et al. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study. J Psychopharmacol. 2014 Mar 26; 28(8):733–744.
   PubMed Web of Science ®Google Scholar
• van den Brink W, Aubin HJ, Bladstrom A, et al. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 2013 Sep–Oct;48(5):570–578.
   PubMed Web of Science ®Google Scholar
• Lynch WJ, Bond C, Breslin FJ, et al. Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. Psychopharmacology (Berl). 2011 Sep;217(1):3–12.
   PubMed Web of Science ®Google Scholar
• Moore CF, Lycas MD, Bond CW, et al. Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol’s reinforcing effects in male alcohol preferring (P) rats. Exp Clin Psychopharmacol. 2014 Feb;22(1):35–42.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000 Aug 23–30;284(8):963–971.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Pierucci-Lagha A, Feinn R, et al. Effects of ondansetron in early-versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res. 2003 Jul;27(7):1150–1155.
   PubMed Web of Science ®Google Scholar
• Muller CA, Geisel O, Banas R, et al. Current pharmacological treatment approaches for alcohol dependence. Expert Opin Pharmacother. 2014 Mar;15(4):471–481.
   PubMed Web of Science ®Google Scholar
• Thompson MD, Kenna GA. Variation in the serotonin transporter gene and alcoholism: risk and response to pharmacotherapy. Alcohol Alcohol. 2016 Mar;51(2):164–171.
   PubMed Web of Science ®Google Scholar
• Bauer IE, Graham DP, Soares JC, et al. Serotonergic gene variation in substance use pharmacotherapy: a systematic review. Pharmacogenomics. 2015;16(11):1307–1314.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 2011 Mar;168(3):265–275.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Seneviratne C, Wang XQ, et al. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am J Psychiatry. 2013 Sep;170(9):1020–1031.
   PubMed Web of Science ®Google Scholar
• Cunningham MO, Woodhall GL, Thompson SE, et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci. 2004 Sep;20(6):1566–1576.
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000 Feb 18;280(2):107–110.
   PubMed Web of Science ®Google Scholar
• Bonnet U, Banger M, Leweke FM, et al. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry. 1999 May;32(3):107–109.
   PubMed Web of Science ®Google Scholar
• Bozikas V, Petrikis P, Gamvrula K, et al. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):197–199.
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Rosenthal RN, Tross S, et al. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 2006 Jan–Feb;15(1):76–84.
   PubMed Web of Science ®Google Scholar
• Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry. 1998 Nov;155(11):1632.
   PubMed Web of Science ®Google Scholar
• Rustembegovic A, Sofic E, Tahirovic I, et al. A study of gabapentin in the treatment of tonic-clonic seizures of alcohol withdrawal syndrome. Med Arh. 2004;58(1):5–6.
   PubMedGoogle Scholar
• Voris J, Smith NL, Rao SM, et al. Gabapentin for the treatment of ethanol withdrawal. Subst Abus. 2003 Jun;24(2):129–132.
   PubMedGoogle Scholar
• Leung JG, Hall-Flavin D, Nelson S, et al. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015 Aug;49(8):897–906.
   PubMed Web of Science ®Google Scholar
• Pani PP, Trogu E, Pacini M, et al. Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev. 2014;2:CD008544.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Quello S, Goodell V, et al. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014 Jan;174(1):70–77.
   PubMed Web of Science ®Google Scholar
• Anton RF, Myrick H, Baros AM, et al. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009 Aug;29(4):334–342.
   PubMed Web of Science ®Google Scholar
• Lyon J. More treatments on deck for alcohol use disorder. JAMA. 2017 Jun 13;317(22):2267–2269.
   Web of Science ®Google Scholar
• Gibbs JW 3rd, Sombati S, DeLorenzo RJ, et al. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41(Suppl 1):S10–6.
   PubMed Web of Science ®Google Scholar
• Skradski S, White HS. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia. 2000;41(Suppl 1):S45–7.
   PubMed Web of Science ®Google Scholar
• Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 2003 Aug 6;23(18):7069–7074.
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46(8):1097–1104.
   PubMed Web of Science ®Google Scholar
• Leggio L, Schwandt ML. Topiramate for alcoholism treatment: novel pharmacogenetic evidence for the journey to personalized medicine? Int J Neuropsychopharmacol. 2014 Oct;17(10):1541–1544.
   PubMed Web of Science ®Google Scholar
• Ait-Daoud N, Malcolm RJ Jr., Johnson BA. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav. 2006 Sep;31(9):1628–1649.
   PubMed Web of Science ®Google Scholar
• Farook JM, Morrell DJ, Lewis B, et al. Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. Alcohol Alcohol. 2007 Jul–Aug;42(4):296–300.
   PubMed Web of Science ®Google Scholar
• Gabriel KI, Cunningham CL. Effects of topiramate on ethanol and saccharin consumption and preferences in C57BL/6J mice. Alcohol Clin Exp Res. 2005 Jan;29(1):75–80.
   PubMed Web of Science ®Google Scholar
• Hargreaves GA, McGregor IS. Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. Alcohol Clin Exp Res. 2007 Nov;31(11):1900–1907.
   PubMed Web of Science ®Google Scholar
• Nguyen SA, Malcolm R, Middaugh LD. Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse. 2007 Mar;61(3):150–156.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003 May 17;361(9370):1677–1685.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007 Oct 10;298(14):1641–1651.
   PubMed Web of Science ®Google Scholar
• Blodgett JC, Del Re AC, Maisel NC, et al. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014 Jun;38(6):1481–1488.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, De Vita O, et al. Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol. 2014 Dec;34(6):709–715.
   PubMed Web of Science ®Google Scholar
• Ray LA, Miranda R Jr., MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009 Apr;17(2):122–129.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Wetherill R, Feinn R, et al. Posttreatment effects of topiramate treatment for heavy drinking. Alcohol Clin Exp Res. 2014 Dec;38(12):3017–3023.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Armeli S, Wetherill R, et al. Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking. Addict Biol. 2016 Mar;21(2):450–459.
   PubMed Web of Science ®Google Scholar
• Knapp CM, Ciraulo DA, Sarid-Segal O, et al. Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 2015 Feb;35(1):34–42.
   PubMed Web of Science ®Google Scholar
• Crunelle CL, Miller ML, Booij J, et al. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol. 2010 Feb;20(2):69–79.
   PubMed Web of Science ®Google Scholar
• Froehlich JC, Fischer SM, Dilley JE, et al. Combining varenicline (Chantix) with naltrexone decreases alcohol drinking more effectively than does either drug alone in a rodent model of alcoholism. Alcohol Clin Exp Res. 2016 Sep;40(9):1961–1970.
   PubMed Web of Science ®Google Scholar
• Gowin JL, Vatsalya V, Westman JG, et al. The effect of varenicline on the neural processing of fearful faces and the subjective effects of alcohol in heavy drinkers. Alcohol Clin Exp Res. 2016 May;40(5):979–987.
   PubMed Web of Science ®Google Scholar
• Mitchell JM, Teague CH, Kayser AS, et al. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl). 2012 Oct;223(3):299–306.
   PubMed Web of Science ®Google Scholar
• Crunelle CL, Schulz S, de Bruin K, et al. Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats. Eur Neuropsychopharmacol. 2011 Feb;21(2):205–210.
   PubMed Web of Science ®Google Scholar
• Nocente R, Vitali M, Balducci G, et al. Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction? Am J Addict. 2013 Sep–Oct;22(5):453–459.
   PubMed Web of Science ®Google Scholar
• Ray LA, Courtney KE, Ghahremani DG, et al. Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. Am J Drug Alcohol Abuse. 2015 Jan;41(1):35–44.
   PubMed Web of Science ®Google Scholar
• Schacht JP, Anton RF, Randall PK, et al. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl). 2014 Sep;231(18):3799–3807.
   PubMed Web of Science ®Google Scholar
• Erwin BL, Slaton RM. Varenicline in the treatment of alcohol use disorders. Ann Pharmacother. 2014 Nov;48(11):1445–1455.
   PubMed Web of Science ®Google Scholar
• Childs E, Roche DJ, King AC, et al. Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements. Alcohol Clin Exp Res. 2012 May;36(5):906–914.
   PubMed Web of Science ®Google Scholar
• Hays JT, Croghan IT, Schroeder DR, et al. Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study. J Subst Abuse Treat. 2011 Jan;40(1):102–107.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Ryan ML, Fertig JB, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013 Jul–Aug;7(4):277–286.
   PubMed Web of Science ®Google Scholar
• McKee SA, Harrison EL, O’Malley SS, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009 Jul 15;66(2):185–190.
   PubMed Web of Science ®Google Scholar
• Meszaros ZS, Abdul-Malak Y, Dimmock JA, et al. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. J Clin Psychopharmacol. 2013 Apr;33(2):243–247.
   PubMed Web of Science ®Google Scholar
• Plebani JG, Lynch KG, Rennert L, et al. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend. 2013 Dec 1;133(2):754–758.
   PubMed Web of Science ®Google Scholar
• Fucito LM, Toll BA, Wu R, et al. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl). 2011 Jun;215(4):655–663.
   PubMed Web of Science ®Google Scholar
• de Bejczy A, Lof E, Walther L, et al. Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial. Alcohol Clin Exp Res. 2015 Nov;39(11):2189–2199.
   PubMed Web of Science ®Google Scholar
• Falk DE, Castle IJ, Ryan M, et al. Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory analysis. J Addict Med. 2015 Jul–Aug;9(4):296–303.
   PubMed Web of Science ®Google Scholar
• ANSM. Recommandation Temporaire d’Utilisation (RTU) du baclofène dans le traitement de l’alcoolo-dépendance. 2014 [cited 2014 Aug 18]. Available from: http://ansm.sante.fr/var/ansm_site/storage/original/application/2976e3c2bb5c0e5265a35955df5e8de0.pdf
   Google Scholar
• Colombo G, Agabio R, Carai MA, et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: i–preclinical evidence. Alcohol Clin Exp Res. 2000 Jan;24(1):58–66.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002 Sep–Oct;37(5):504–508.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007 Dec 8;370(9603):1915–1922.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010 Nov;34(11):1849–1857.
   PubMed Web of Science ®Google Scholar
• Colombo G, Addolorato G, Agabio R, et al. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res. 2004;6(5):403–414.
   PubMed Web of Science ®Google Scholar
• Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 2005 Mar–Apr;40(2):147–150.
   PubMed Web of Science ®Google Scholar
• Muller CA, Geisel O, Pelz P, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015 Aug;25(8):1167–1177.
   PubMed Web of Science ®Google Scholar
• Beraha EM, Salemink E, Goudriaan AE, et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol. 2016 Dec;26(12):1950–1959.
   PubMed Web of Science ®Google Scholar
• Reynaud M, Aubin HJ, Trinquet F, et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study. Alcohol Alcohol. 2017;19:1–8.
   Google Scholar
• Hauser P, Fuller B, Ho SB, et al. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction. 2017 Jul;112(7):1173–1183.
   PubMed Web of Science ®Google Scholar
• Pignon B, Labreuche J, Auffret M, et al. The dose-effect relationship of baclofen in alcohol dependence: a 1-year cohort study. Hum Psychopharmacol. 2017 May 18.
   PubMedGoogle Scholar
• Farokhnia M, Schwandt ML, Lee MR, et al. Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. Transl Psychiatry. 2017 Apr 25;7(4):e1108.
   PubMed Web of Science ®Google Scholar
• Chick J, Nutt DJ. Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol. 2012 Feb;26(2):205–212.
   PubMed Web of Science ®Google Scholar
• Fadda P, Scherma M, Fresu A, et al. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse. 2003 Oct;50(1):1–6.
   PubMed Web of Science ®Google Scholar
• Cabrera EA, Wiers CE, Lindgren E, et al. Neuroimaging the effectiveness of substance use disorder treatments. J Neuroimmune Pharmacol. 2016 Sep;11(3):408–433.
   PubMed Web of Science ®Google Scholar
• Kamal RM, van Noorden MS, Franzek E, et al. The neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: a review. Neuropsychobiology. 2016;73(2):65–80.
   PubMed Web of Science ®Google Scholar
• Bay T, Eghorn LF, Klein AB, et al. GHB receptor targets in the CNS: focus on high-affinity binding sites. Biochem Pharmacol. 2014 Jan 15;87(2):220–228.
   PubMed Web of Science ®Google Scholar
• Caputo F, Vignoli T, Tarli C, et al. A brief up-date of the use of sodium oxybate for the treatment of alcohol use disorder. Int J Environ Res Public Health. 2016 Mar;13(3):290.
   PubMed Web of Science ®Google Scholar
• Gallimberti L, Ferri M, Ferrara SD, et al. gamma-Hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res. 1992 Aug;16(4):673–676.
   PubMed Web of Science ®Google Scholar
• Caputo F, Addolorato G, Lorenzini F, et al. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend. 2003 May 01;70(1):85–91.
   PubMed Web of Science ®Google Scholar
• Caputo F, Addolorato G, Stoppo M, et al. Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. Eur Neuropsychopharmacol. 2007 Dec;17(12):781–789.
   PubMed Web of Science ®Google Scholar
• Nava F, Premi S, Manzato E, et al. Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionst. J Psychoactive Drugs. 2006 Sep;38(3):211–217.
   PubMed Web of Science ®Google Scholar
• Leone MA, Vigna-Taglianti F, Avanzi G, et al. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010 Feb;17(2):CD006266.
   Google Scholar
• Dom G, Moggi F. Co-occurring addictive and psychiatric disorders. Heidelberg (NY): Springer; 2015.
   Google Scholar
• Fehr C, Coste F, Rahhali N, et al. Die Behandlungswirklichkeit alkoholabhängiger Patienten in der täglichen medizinischen Praxis in Deutschland. Suchtmed. 2015;17(5):233–246.
   Google Scholar
• Nalpas B, Perney P. Use of psychoactive medication in short- and long-term abstainers from alcohol. Alcohol Alcohol. 2017 Apr;04:1–6.
   Google Scholar
• Foulds JA, Adamson SJ, Boden JM, et al. Depression in patients with alcohol use disorders: systematic review and meta-analysis of outcomes for independent and substance-induced disorders. J Affect Disord. 2015 Oct;01(185):47–59.
   Web of Science ®Google Scholar
• Iovieno N, Tedeschini E, Bentley KH, et al. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Aug;72(8):1144–1151.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004 Apr 21;291(15):1887–1896.
   PubMed Web of Science ®Google Scholar
• Torrens M, Fonseca F, Mateu G, et al. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 2005 Apr 4;78(1):1–22.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Chung T, Douaihy AB, et al. Mirtazapine in comorbid major depression and an alcohol use disorder: a double-blind placebo-controlled pilot trial. Psychiatry Res. 2016 Aug;30(242):326–330.
   Web of Science ®Google Scholar
• Kishi T, Sevy S, Chekuri R, et al. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. J Clin Psychiatry. 2013 Jul;74(7):e642–54.
   PubMed Web of Science ®Google Scholar
• Anton RF, Kranzler H, Breder C, et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008 Feb;28(1):5–12.
   PubMed Web of Science ®Google Scholar
• Brunetti M, Di Tizio L, Dezi S, et al. Aripiprazole, alcohol and substance abuse: a review. Eur Rev Med Pharmacol Sci. 2012 Oct;16(10):1346–1354.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Orsolini L, Fornaro M, et al. Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opin Investig Drugs. 2016 Jun;25(6):719–728.
   PubMed Web of Science ®Google Scholar
• Ray LA, Heydari A, Zorick T. Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. Drug Alcohol Rev. 2010 Sep;29(5):568–575.
   PubMed Web of Science ®Google Scholar
• Guardia J, Roncero C, Galan J, et al. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. Addict Behav. 2011 Mar;36(3):265–269.
   PubMed Web of Science ®Google Scholar
• Katz DA, Locke C, Liu W, et al. Single-dose interaction study of the arginine vasopressin type 1B receptor antagonist ABT-436 and alcohol in moderate alcohol drinkers. Alcohol Clin Exp Res. 2016 Apr;40(4):838–845.
   PubMed Web of Science ®Google Scholar
• Ryan ML, Falk DE, Fertig JB, et al. A phase 2, double-blind, placebo-controlled randomized trial assessing the efficacy of ABT-436, a novel V1b receptor antagonist, for alcohol dependence. Neuropsychopharmacology. 2017 Apr;42(5):1012–1023.
   PubMed Web of Science ®Google Scholar
• Malcolm R, Myrick H, Roberts J, et al. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002 May;17(5):349–355.
   PubMed Web of Science ®Google Scholar
• Mueller TI, Stout RL, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997 Feb;21(1):86–92.
   PubMed Web of Science ®Google Scholar
• Brady KT, Myrick H, Henderson S, et al. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002 Aug 1;67(3):323–330.
   PubMed Web of Science ®Google Scholar
• Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;21(2):55–64.
   PubMed Web of Science ®Google Scholar
• Thompson A, Ashcroft DM, Owens L, et al. Drug therapy for alcohol dependence in primary care in the UK: a clinical practice research datalink study. PLoS One. 2017;12(3):e0173272.
   PubMed Web of Science ®Google Scholar